Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

European Investor LSP Raises $600M For Life Sciences Fund

Executive Summary

LSP says its new fund for medical device and drug development companies will be the biggest fund dedicated to life sciences companies in Europe.

You may also be interested in...



Thermo Fisher Scientific Announces $11.5Bn Buyout Of Qiagen

Thermo Fisher expects the deal to improve its portfolio of specialty diagnostics for clinical labs while its genetic analysis technologies, biosciences reagents and consumable products will complement Qiagens’ sample preparation and assay technologies.

Femtech Start-Ups Fueling Change In Women’s Health

Start-ups focused on women's health are pioneering a revolution in the tech market. Medtech Insight spotlights four innovative femtech companies trying to shape the future of women’s health.

Sequana Medical Secures $21M In Private Placement

One year on from its IPO on Euronext Brussels, abdominal implant maker Sequana Medical has secured €19m ($21m) in an equity placement. The company said it had been backed by new and existing investors. 

Topics

Related Companies

UsernamePublicRestriction

Register

MT126367

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel